Dr Martens stock was down nearly 13% last week – is it time to buy or sell?

Dr Martens stock, the iconic bootmaker, registered a noteworthy drop in its share price last week and I want to know if this is time to take action.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As one of the most recognisable footwear brands, Dr Martens (LSE: DOCS) was a new addition to the London Stock Exchange in 2021. While results are impressive, recent selling leaves me curious. For the week commencing 10 January 2021, the share price is down nearly 13%. Let’s take a closer look.

Encouraging results

Since its IPO in January 2021, Dr Martens stock has been volatile. From a yearly high of 521p, the share price currently sits around 365p. Not long after the IPO, the company released quarterly figures for the year ending March 2021. This was to provide greater clarity on where the share price might go in the future. The results showed year-on-year changes of -14% (Q1), 42% (Q2), 9% (Q3), and 19% (Q4). These positive results continued with a 64% increase in revenue in a trading statement in June 2021.

The main reason for these impressive recent results was the reopening of Dr Martens stores around the world. This is especially true in the US and Europe, with Japan still lagging. The US has been the most lucrative market for this stock, registering 106% growth in sales. Indeed, Barclays upgraded the company in December 2021 because of its ability to continue to grow revenue through its recognisable products. The first-half results in 2021, for the six months up to 30 September, gave me a lot of confidence as a potential investor, because global profit expanded by 65%. In addition, interim earnings-per-share increased 60%. With a dividend of £0.012 per share, I am pleased that most of the profits attributable to shareholders are being kept within the company. This enables further growth.

Why the drop in share price?

In spite of good results, the share price tumbled 11% in one day in early January 2022. This was solely due to the sale of 65m shares by private equity firm Permira. This company was in fact responsible for the listing of Dr Martens in January 2021. On closer inspection, the sale amounted to about one-seventh of Permira’s original holding. The private equity firm now owns 36% instead of the original 42%. This is hardly something I’m worried about.

While sales in the US are growing at a phenomenal rate, supply chain issues are starting to eat into the operation. This is likely due to the hangover from the Covid-19 pandemic and should subside in the near term. Nonetheless, the management has decided to add £10 to the price of boots to offset this problem. This price rise will also go some way to alleviating cost increases in raw materials and shipping. Furthermore, Dr Martens’ price-to-earnings (P/E) ratio of 68 is only slightly above the industry average of 64. Barclays has, however, hinted that given the company’s short track record it is difficult to currently value this stock.

I like this product and the recent growth of the company around the world is a very good sign. It seems that more results are required to achieve an accurate company valuation. While I won’t be buying these shares just now, I will not be ruling them out in the future.    

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Andrew Woods has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »